Pacira publishes positive two-year Phase 1 data for PCRX-201 gene therapy in knee osteoarthritis - PCRX News | RalliesPacira publishes positive two-year Phase 1 data for PCRX-201 gene therapy in knee osteoarthritis
P
PCRX• Two-year Phase 1 results published for PCRX-201
- Pacira Biosciences reported publication of two-year Phase 1 results for PCRX-201, its investigational gene therapy for knee osteoarthritis.
- Results were already presented via the journal publication, showing the single knee injection was generally well tolerated.
- Exploratory measures indicated sustained improvement in pain, stiffness, function through two years among patients who stayed in follow-up.
- Glucocorticoid pre-treatment appeared to improve tolerability and outcomes, shaping the ongoing Phase 2 ASCEND trial design.
- Phase 2 ASCEND topline results remain on track for a first readout at year-end 2026.
•
